"Bristol Myers Squibb, bluebird land once-high-stakes approval on BCMA CAR-T — and it bodes well for rival J&JAmber TongSenior Editor
Almost a year after getting slammed by a surprise refuse-to-file letter, Bristol Myers Squibb and bluebird have been cleared to market the first BCMA CAR-T therapy.Once a closely-watched event, the approval of ide-cel in multiple myeloma received a relatively muted welcome when it was announced Friday afternoon.
It was largely expected by analysts, who were however surprised by parts of the label.The drug, now dubbed Abecma, will sport a list price of $419,500.
The OK marked a much-needed victory — coming on the heels of another win on liso-cel, or Breyanzi — for both companies after regulatory setbacks that led to the overnight evaporation of a $6 billion CVR that Celgene investors got from Bristol and serious credibility issues for bluebird.
“Bristol Myers Squibb is now the only company with two approved CAR T cell therapies with distinct targets of CD19 and BCMA,” said Bristol CMO Samit Hirawat.
The pharma giant will now split promotion costs and profit with the yet-unnamed oncology newco that bluebird is spinning out as CEO Nick Leschly separates the rare disease and cancer pipelines.Regulators, who had spurned the initial BLA because it included a faulty section on CMC, gave thumbs up to the data from the pivotal Phase II KarMMa trial. Among 100 patients taking the full dose of ide-cel, 72% saw their tumor shrink — and 28% achieved a stringent complete response. An estimated 65% of those had remission lasting at least 12 months, bolstering Bristol’s claim to a durable effect. Median time to response was just 30 days, they added.“We were surprised by a few aspects of the label: Abecma was approved for 5L+, versus our expectation of 4L+, and HLH was included as a black box warning,” Stifel analyst Benjamin Burnett wrote. “However, after reflecting on these points with a KOL (tertiary care physician who leads CAR-T efforts at his institution), we think neither will significantly impact adoption.”
Biren Amin of Jefferies, meanwhile, noted that the approved dose range of 300-400 million cells was narrower than expected. He added that the approval bodes well for J&J-partnered Legend Biotech, whose BCMA CAR-T, cilta-cel, has a PDUFA date lined up for this year.Still, Bristol has been throwing its weight behind ide-cel, so confident about its status as a frontrunner that it ejected a second BCMA CAR-T candidate (orva-cel, originally developed by Juno) from the pipeline, writing off $470 million in the process.At least some investors were energized, bidding bluebird shares $BLUE up 8.27% to $32.46."
The above is the write for the latest Car T approved by the FDA. Note only a 28% CR rate, 72% with partial response. 65% of patients having remission of at least 12months. Approval after a phase 2 trial of 100 patients. Treatment target cost $US 419500.
- Forums
- ASX - By Stock
- CHM
- valuation thoughts
valuation thoughts, page-23
-
- There are more pages in this discussion • 358 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.40M |
Open | High | Low | Value | Volume |
1.5¢ | 1.6¢ | 1.5¢ | $9.713K | 647.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 1583064 | 1.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.6¢ | 540939 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 1516398 | 0.015 |
8 | 1644261 | 0.014 |
3 | 516666 | 0.013 |
3 | 83416 | 0.012 |
3 | 254041 | 0.011 |
Price($) | Vol. | No. |
---|---|---|
0.016 | 569767 | 2 |
0.017 | 617827 | 2 |
0.018 | 200000 | 3 |
0.019 | 1948702 | 6 |
0.020 | 1223093 | 5 |
Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |